ProKidney Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $346.8M
- Price
- $1.66
- % Change (Daily % change from the live per-ticker quote feed.)
- +5.73%
- Volume
- 1.1M
About
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Quick stats
Shares outstanding208.9M
Computed float88.1M
Float / shares42.2%
Cash runway (months)11
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001850270
Websitehttps://www.prokidney.com
AI Summary
AI-generated1/9
minorbullishclinical trial
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
ProKidney will present eight abstracts, including one oral presentation, at ASN Kidney Week 2026 in Denver, October 21-25.
The data span translational CKD models and drug product characterization supporting a multifactorial mechanism of action for rilparencel, plus a pooled Phase 2 analysis of patients meeting key PROACT 1 criteria showing strong safety and kidney function stabilization in advanced CKD with type 2 diabetes.
Management says the findings strengthen confidence in the ongoing Phase 3 PROACT 1 study, with cash runway expected into mid-2027.
Red flags
- pooled Phase 2 subset analysis may not be indicative of Phase 3 PROACT 1 results
- cash runway only into mid-2027, raising potential future financing risk